The American Society of Addiction Medicine (ASAM) has released new clinical practice guidelines for benzodiazepine tapering, providing evidence-based recommendations for all healthcare professionals managing patients on long-term benzodiazepine therapy. These guidelines are particularly important for clinicians managing patients who are prescribed opioids alongside benzodiazepines, given the significant risks associated with this combination.
Why These Guidelines Matter
Benzodiazepines, while effective for short-term management of anxiety, insomnia, and other conditions, can lead to physical dependence and pose serious risks when used long-term. The concurrent use of benzodiazepines and opioids significantly increases the risk of respiratory depression, overdose, and death. As a prescriber, understanding how to safely taper benzodiazepines is essential for patient safety and improved outcomes.
Key Recommendations for Prescribers
- Medical and psychiatric history
- Benzodiazepine use pattern
- Risk factors for complicated withdrawal
- Support systems
The decision to taper should be collaborative, involving shared decision-making with the patient to establish goals, timeline, and expectations.
- Individualized to each patient’s needs
- Flexible and adjustable based on patient response
- Developed with patient input to enhance adherence
- Gradual enough to minimize withdrawal symptoms
- Initial dose reductions of 5-25%
- Allow 1-2 weeks between dose reductions to assess tolerance
- Slower tapers (5-10%) for patients on long-term therapy
- Consider even slower tapers (5% or less) as doses get smaller
- Prioritize which medication to taper first based on individual risk assessment
- Consider tapering benzodiazepines first when possible
- Implement enhanced monitoring during the taper process
- Never abruptly discontinue either medication
- Monitoring for and addressing withdrawal symptoms promptly
- Considering adjunctive medications to manage specific symptoms
- Providing psychosocial support throughout the taper
- Implementing non-pharmacological approaches for symptom management
- Cognitive-behavioral therapy for anxiety and insomnia
- SSRIs or SNRIs for anxiety disorders
- Sleep hygiene education and non-benzodiazepine approaches for insomnia
- Mindfulness and relaxation techniques
Implementation in Practice
To implement these guidelines:
- Identify patients who might benefit from benzodiazepine tapering, especially those on concurrent opioid therapy
- Discuss risks and benefits of long-term benzodiazepine use with patients
- Develop individualized tapering plans with patient input
- Provide close follow-up and adjust plans as needed
- Offer or refer for psychosocial support throughout the process
Conclusion
The new ASAM guidelines provide a framework for safely tapering benzodiazepines while minimizing patient discomfort and withdrawal complications. For prescribers managing patients on benzodiazepines, especially those also prescribed opioids, these guidelines offer practical, evidence-based approaches to reduce risks while maintaining patient-centered care.
We encourage all prescribers to review the complete guidelines and pocket guide available on the ASAM website and incorporate these recommendations into practice to improve patient safety and outcomes.
*Note: This blog post provides an overview of key recommendations. Prescribers should consult the complete ASAM guidelines for comprehensive information on benzodiazepine tapering here: https://www.asam.org/quality-care/clinical-guidelines/benzodiazepine-tapering